skip to main content
Ram Mishra


Dr. Ram Mishra is a Professor in the Department of Psychiatry and Behavioural Neurosciences and a Co-Director in the School of Biomedical Engineering. He is an internationally well-known scientist and pioneer in the field of dopamine, neuropeptides, receptor function, schizophrenia and Parkinson's Disease. His research extends from molecular and behavioural etiological functions to drug discovery, drug delivery, and commercialization. 

Featured Publications

  • J. Piazza, T. Hoare, L. Molinaro, K. Terpstra, J. Bhandari, R. Selvaganapathy, B. Gupta,R.K. Mishra. Intranasally Administered Lectin Functionalized poly(ethylene glycol)-blockpoly(D,L)-lactic-co-glycolic acid (PEG-PLGA) Nanoparticles for the Treatment of Schizophrenia. European journal of pharmaceutics and biopharmaceutics. 87(1):30-9, 2014.PMID 24560967.
  • R.P. Daya, J.K. Bhandari, P.A. Hui, Y. Tian, T. Farncombe, and R.K. Mishra. Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function utilizing PET and CT fused imaging in live rats. Neuropharmacology, 77:325-33, 2014. PMID: 24140927.
  • D. Basu, Y. Tian, J. Bhandari, J.R. Jiang, P. Hui, R.L. Johnson, and R.K. Mishra. Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization. PloS one, 8(8): e70736, 2013. PubMed ID 23940634.
  • M. L. Tan, B.A. Dyck, J. Gabriele, R. P. Daya, N. Thomas, C. D. R. Sookram, D. Basu, M. Ferro, and R. K. Mishra. Synapsin II Expression in the Dorsolateral Prefrontal Cortex of Brain Specimens from Patients with Schizophrenia and Bipolar Disorder. Pharmacogenomics.14(1): 63-9, 2013. PMID 23529008.
  • M.G.R Beyaert, R.P. Daya, B.A. Dyck, R.L. Johnson and R.K. Mishra. PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. European Neuropsychopharmacology. 23, 253-262, 2013. PMID 22658400.


  • PhD (Memorial Univ. Canada), 1973
  • CIHR - Post-doctoral fellow (Albert Einstein College of Medicine, New York), 1973 - 1976

Research Areas

Research in Dr. Mishra's laboratory focuses on the relationship between genetic, biochemical, and molecular mechanisms and neuropsychiatric disorders such as schizophrenia and Parkinson's disease. The research team is particularly interested in the role of dopamine receptors in various disease processes, where understanding the molecular basis of their dysfunction could contribute to potential improvements in either disease detection or treatment. The laboratory has been uninterruptedly funded from CIHR, NSERC, and OMHF for the last several years and currently receives major funding from these agencies.

The following projects are currently active in the lab:

a) Role of synapsin II in the pathophysiology of schizophrenia: Recent efforts have led to the discovery of novel mechanisms suggesting that synapsin II may be one of the underlying causal factors in the pathophysiology of schizophrenia.

b) Development of allosteric drugs targeting dopamine D2L receptors: Recent work has led to the discovery of novel compounds that may be useful for the treatment of negative, positive, and cognitive symptoms of schizophrenia.

c) Role of apoptosis-inducing factor (AIF) in typical antipsychotic drug-induced cell death: Recent work led to the discovery of caspase-independent mechanisms for cell death induced by haloperiodol treatment in humans.

d) Role of conserved dopamine neurotrophic factor (CDNF) and cyclin-dependent kinase 5 (Cdk5) in neurodevelopment. 

© 2018 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | 905-525-9140 | Contact Us | Terms of Use & Privacy Policy